Compare CAPL & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPL | BIOA |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.5M | 681.9M |
| IPO Year | 2012 | N/A |
| Metric | CAPL | BIOA |
|---|---|---|
| Price | $22.58 | $16.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 47.2K | ★ 336.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ 96.15 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,869,806,000.00 | N/A |
| Revenue This Year | N/A | $720.93 |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $88.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.61 | $3.79 |
| 52 Week High | $23.34 | $24.00 |
| Indicator | CAPL | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 45.81 |
| Support Level | $20.17 | $15.74 |
| Resistance Level | $22.99 | $19.46 |
| Average True Range (ATR) | 0.69 | 1.34 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 75.08 | 41.98 |
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.